Trials

Investigator-sponsored Phase 1 study of AAVrh.10hFXN frataxin gene transfer in Friedreich-ataxia cardiomyopathy.

Phase 2 VacSYn study of an alpha-synuclein peptide-conjugate active immunotherapy in early Parkinson's disease.

First-in-human Phase 1 study of the brain-penetrant NLRP3 inhibitor ACI-19764 in healthy adults and adults with cardiovascular risk factors.

Phase 3 study of an LPA1 antagonist in idiopathic pulmonary fibrosis.

Phase 3 study of the LPA1 antagonist admilparant in progressive pulmonary fibrosis.

"This database keeps track of the previous and ongoing clinical trials, alongside their outcomes. The aim of this database is to give people the ability to easily query for their trial of interest and stay up to date on the latest results. In sum, this database will give an overview of the current pharmacological strategies that have been applied to target human aging"

Completed aging-frailty study evaluating the safety and potential functional effects of intravenous allogeneic mesenchymal stem-cell infusion.

Phase 1 study evaluating safety and efficacy of intravenous cultured allogeneic adult umbilical-cord-derived mesenchymal stem cells for aging frailty.

Phase 1/2a study of the ATR inhibitor ART0380 alone and with gemcitabine or irinotecan in advanced solid tumors.

Completed Phase 1/2a dose-escalation and expansion study of a lysyl oxidase inhibitor in myelofibrosis.

Phase 1/2a POLKA study of the DNA polymerase theta inhibitor ART6043 alone and with olaparib.

Phase 3 comparison of the direct telomere-targeting nucleoside ateganosine sequenced with cemiplimab against investigator-selected chemotherapy in advanced NSCLC.

Dose-finding Phase 2 study of a telomerase-recognized telomere-targeting nucleoside followed by PD-1 blockade in advanced NSCLC.

Registered Phase 2 study of the selective mTORC1 inhibitor AV078 in refractory epilepsy caused by tuberous sclerosis complex.

Pivotal Phase 3 safety and efficacy study of FLT201 gene therapy in Gaucher disease type 1.

Disease-prevention Phase 2 dose-finding study of mTOR-pathway inhibition in older adults at elevated risk of respiratory tract infection.

Phase 2a placebo-controlled study of intravenous BI 765423 in idiopathic pulmonary fibrosis.

Healthy-aging Phase 2 trial testing whether six months of calcium alpha-ketoglutarate changes DNA-methylation-derived biological age in middle-aged adults.

links directly to clinicaltrials.gov for all clincial trials of each company on the site's list of aging companies

Study evaluating two years of oral danazol in people with telomere-related bone-marrow or lung disorders, with attenuation of accelerated telomere attrition as the primary outcome.

Pilot study evaluating the safety and feasibility of intermittent dasatinib plus quercetin dosing in older adults with slow gait and mild cognitive impairment who are at risk for Alzheimer's disease.

Proof-of-concept pilot study evaluating the safety, feasibility, and cerebrospinal-fluid penetration of intermittent dasatinib plus quercetin in older adults with early Alzheimer's disease.

Randomized placebo-controlled Phase 2 study evaluating intermittent dasatinib plus quercetin senolytic therapy for safety, feasibility, and efficacy in older adults with tau-positive amnestic mild cognitive impairment or early Alzheimer's disease.

Open-label pilot study evaluating the safety, tolerability, and feasibility of intermittent dasatinib plus quercetin senolytic therapy in adults with mild cognitive impairment or Alzheimer's disease.

Disease-specific Phase 2 study testing whether intermittent dasatinib plus quercetin changes senescent-cell burden in people with chronic kidney disease.

Phase 2 study evaluating whether senolytic regimens alter senescent-cell burden and bone turnover markers in older women.

Open-label pilot study evaluating two short senolytic regimens, dasatinib plus quercetin and fisetin alone, using walking speed and blood p16INK4a senescent-cell abundance as primary measures in adult childhood-cancer survivors.

Randomized clinical trial evaluating senolytic dasatinib plus quercetin and nicotinamide riboside in osteoporosis framed as accelerated skeletal aging.

Phase 2 study designed to test digoxin as a senolytic intervention in people with systolic heart failure and type 2 diabetes.

Open-label single-arm pilot study evaluating four weeks of daily subcutaneous elamipretide for safety, tolerability, inflammatory biomarkers, skeletal-muscle health, aerobic capacity, and cognitive function in older adults.

First-in-human single-dose study evaluating the safety and tolerability of an AAV-delivered, doxycycline-activated OSK partial epigenetic reprogramming therapy in adults with optic neuropathies.

Placebo-controlled study evaluating daily or weekly everolimus for physiological and molecular hallmarks of aging in older adults with insulin resistance or prediabetes.

Pilot randomized placebo-controlled study evaluating whether fisetin reduces frailty and markers of inflammation, insulin resistance, and bone resorption in older adults.

Pilot randomized trial evaluating whether fisetin reduces senescent-cell markers and improves six-minute walk distance in people with peripheral arterial disease.

Pilot clinical trial evaluating intermittent fisetin for vascular endothelial function and aortic stiffness in older adults, including cellular-senescence and circulating SASP measures.

Placebo-controlled pilot study evaluating fisetin pharmacokinetics, safety, chronic-inflammation measures, senescent-cell measures, and general-health measures in healthy volunteers and older adults with multimorbidity.

Randomized double-blind placebo-controlled pilot study evaluating short-course fisetin effects on lung function and biomarkers of cellular senescence in older adults.

Randomized placebo-controlled pilot study evaluating fisetin effects on frailty-related physical function and markers of inflammation, insulin resistance, and bone resorption in older women with gait disturbance.

Completed Phase 1/Phase 2 knee-osteoarthritis trial evaluating the senolytic candidate fisetin, with treatment-emergent adverse events as the primary outcome.

Phase 1b/2 study of the eIF2B activator fosigotifator in pediatric and adult participants with vanishing white matter disease.

Phase 1/2/3 program of AAV9-mediated NGLY1 gene transfer in children and adolescents with NGLY1 deficiency.

Multicenter randomized double-blind placebo-controlled study evaluating safety and health-status effects of human umbilical-cord mesenchymal stem-cell infusion in people with aging frailty.

Phase 3 sham-controlled study of an allogeneic disc-derived progenitor cell therapy for symptomatic lumbar disc degeneration.

Phase 1 study of the PARG inhibitor IDE161 as monotherapy and with pembrolizumab in advanced solid tumors.

Phase 3 comparison of the telomerase inhibitor imetelstat with best available therapy after JAK-inhibitor treatment in myelofibrosis.

First-in-human Phase 1/2a study of a PRNP-lowering antisense medicine in symptomatic prion disease.

Randomized double-blind placebo-controlled proof-of-concept study evaluating KH-1, a spermidine, spermidine-derivative, and probiotic nutraceutical, for safety, insulin resistance, glucose homeostasis, and autophagy-related biomarkers.

Phase 2b study of Lomecel-B administered during Stage II surgery for hypoplastic left heart syndrome.

Randomized blinded placebo-controlled study evaluating intravenous Lomecel-B mesenchymal stem cells for safety and influenza-vaccine antibody response in adults with aging frailty.

Multicenter randomized double-blind placebo-controlled Phase 2b study evaluating intravenous allogeneic mesenchymal stem cells in adults with aging frailty, with six-minute walk change as the primary efficacy measure.

extensive list of fields that look straight from clinicaltrials.gov; main page has nice pipeline vs time view as well as a calendar for completion dates all in addition to the main database table view

The AAA's page has several views onto their snapshot of trials including a full report & the top trials tracker, which is a page visualized as a typical pipeline diagram.

Pivotal Phase 2 study of frataxin gene replacement in Friedreich-ataxia cardiomyopathy.

Phase 1/2 dose-escalation study of LX2006 frataxin gene therapy in Friedreich-ataxia cardiomyopathy.

Phase 1/2a study of AAV-based GBA1 gene therapy in Parkinson's disease with a qualifying GBA1 mutation.

Phase 1/2 dose-finding study of AAV-based GBA1 gene therapy in adults with peripheral manifestations of type 1 Gaucher disease.

Phase 1/2 study of AAV-based progranulin gene replacement in frontotemporal dementia caused by GRN mutations.

Placebo-controlled exploratory Phase 2 study evaluating extended-release metformin and a composite assessment of intervention effects on aging in middle-aged and older men.

Randomized placebo-controlled Phase 2 study evaluating metformin for preventing or reducing frailty progression in high-risk older adults, using deficit-accumulation and Fried frailty measures.

Completed Phase 3 trial testing the pro-autophagy effect of metformin in adults with prediabetes using a cellular autophagosome marker.

Randomized placebo-controlled study evaluating twelve weeks of spermidine supplementation on autophagy markers, brain and metabolic health measures, visible aging measures, and safety.

Randomized placebo-controlled study of eight weeks of urolithin A supplementation and muscle mitochondrial quality in frail older adults.

Randomized double-blind placebo-controlled study of four months of Mitopure in healthy adults aged 65 to 90 with evidence of low mitochondrial function.

Randomized double-blind placebo-controlled study evaluating six months of 500 mg or 1,000 mg daily urolithin A supplementation on muscle strength and performance in healthy middle-aged adults.

Randomized double-blind placebo-controlled study evaluating four months of daily 500 mg or 1,000 mg Mitopure supplementation, with change in cycle-ergometer exercise tolerance as the primary outcome.

Randomized placebo-controlled study evaluating 28 days of oral urolithin A supplementation, mitochondrial activity in CD3-positive T cells, and T-cell population measures in healthy adults.

Completed Phase 2 study testing whether the mitochondria-targeted antioxidant MitoQ changes vascular endothelial function in older adults.

Frailty-focused Phase 2 crossover trial testing a mitochondria-targeted antioxidant against vascular, cerebrovascular, cognitive, and mobility endpoints in older adults.

Completed Phase 2a SPRING study of the anti-CCL24 antibody CM-101 in primary sclerosing cholangitis.

Randomized crossover study evaluating nicotinamide riboside supplementation on cognition, mood, and daily activity in people with subjective cognitive decline or mild cognitive impairment.

Randomized double-blind placebo-controlled dose-ranging study, followed by an open-label high-dose cohort, evaluating NMN supplementation in middle-aged and older adults.

Completed placebo-controlled metabolic study of nicotinamide mononucleotide supplementation in postmenopausal women with prediabetes.

Placebo-controlled aging study testing whether NMN changes a prespecified composite biological-age score in middle-aged and older adults.

Randomized double-blind placebo-controlled study evaluating one year of nicotinamide riboside supplementation for physical and cognitive function in frail older adults.

Placebo-controlled study evaluating eight weeks of oral nicotinamide riboside supplementation for neurovascular coupling, brain health, and memory in older adults.

Double-blind randomized placebo-controlled study evaluating nicotinamide riboside supplementation on functional capacity, muscle physiology, muscle quality, and NAD+ content in older veterans.

Phase 2 study testing whether NAD+ precursor supplementation changes systolic blood pressure and arterial stiffness in middle-aged and older adults.

Healthy-aging study testing nicotinamide riboside supplementation alongside exercise training, with skeletal-muscle mitochondrial respiration as the primary outcome.

Phase 2a study optimizing delivery and evaluating safety of retinal pigment epithelial cell replacement in geographic atrophy from dry AMD.

Phase 1b study of a single intracisternal progranulin gene therapy in genetically defined frontotemporal dementia.

Manually curated list of just clinical trials in or past phase 3 (or 2/3), with common mechanisms of action grouped & manual judgement about likelihood of label expansion due to hitting core aging targets that underpin multiple age-related indications.

Phase 1a/1b study of a dual alpha-v-beta-8/alpha-v-beta-1 integrin inhibitor targeting local TGF-beta activation in advanced solid tumors.

Completed Phase 1/2a study of allogeneic mitochondria transplantation in refractory inflammatory myopathy.

Registered placebo-controlled Phase 2 study of mitochondria isolated from allogeneic umbilical-cord-derived mesenchymal stem cells in refractory inflammatory myopathy.

Phase 2 placebo-controlled study examining three months of polyamine supplementation and cognitive performance in healthy older adults with subjective cognitive decline.

Randomized placebo-controlled Phase 2 study evaluating rapamycin safety and clinical measures of aging in older adults.

Translational Phase 2 study of mTOR inhibition with rapamycin in older adults, with measures focused on immune, physical, cognitive, and cardiovascular function.

Randomized double-blind placebo-controlled pilot study evaluating low-dose weekly rapamycin for delaying ovarian aging in perimenopausal women.

Exploratory pharmacokinetic and pharmacodynamic study of rapamycin and everolimus dose and timing in healthy older adults.

list of clinical trials from companies or other organizations, organized by hallmarks, visualized as a typical pipeline diagram; some entries describe pre-clinical programs rather than actual clinical trials (but this is clear from the visualization)

Open-label Phase 1 study of a glucocerebrosidase-targeting small molecule in Parkinson's disease with and without GBA1 mutations.

Registered placebo-controlled Phase 2a study of two GT-02287 dose levels in early Parkinson's disease.

Registered Phase 2 open-label study of KER-065 in ambulatory and nonambulatory participants with Duchenne muscular dystrophy.

Pivotal Phase 2 study of systemic LAMP2B gene replacement in males with Danon disease.

Registered Phase 2 placebo-controlled study of oral RXC008 in participants with Crohn's-disease strictures.

Randomized study evaluating sirolimus effects on phenotypic and functional biomarkers of aging in older adults.

Study characterizing the pharmacokinetics and pharmacodynamics of daily sirolimus and everolimus dose levels in older adults to support future aging-related trials.

Dose-ranging pharmacology study of weekly sirolimus and everolimus intended to identify doses that safely inhibit mTOR and support future trials targeting the biology of aging.

Expanded pilot study evaluating a personalized combination of somatropin, metformin, and DHEA for thymus regeneration, with epigenetic age, thymus regeneration, safety, and tolerability as primary measures.

Pivotal Phase 3 study of the redox-modulating drug sonlicromanol in adults with genetically confirmed m.3243A>G primary mitochondrial disease.